<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445637</url>
  </required_header>
  <id_info>
    <org_study_id>A5481065</org_study_id>
    <nct_id>NCT03445637</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®</brief_title>
  <official_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance(Registered)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study is designated as a Post Marketing Surveillance Study and is a
      commitment to MFDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the approval of IBRANCE® in Korea, as a part of Risk Management Plan (RMP), which is
      required by Ministry of Food and Drug Safety (MFDS), safety and efficacy information of new
      medication will be provided at minimum 3000 subjects administered in the setting of routine
      practice during the initial 6 years after the approval.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related adverse events during first 3 months</measure>
    <time_frame>2018 ~ 2022</time_frame>
    <description>This is a prospective, observational, non-interventional, multi-center study in which subjects will be administered as part of routine practice at Korean health care centers by accredited physicians.</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects enrolled should meet the usual prescribing criteria for IBRANCE® as per the
        Local Product Document (LPD) and should be entered into the study at the physician's
        discretion.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Women of 18 years of age with proven diagnosis of advanced adenocarcinoma of the
             breast (locoregionally recurrent or metastatic disease).

          2. ER+ and/or PgR+ tumor based on local laboratory results :test as per local practice

          3. HER2- breast cancer based on local laboratory results :test as per local practice or
             local guidelines

          4. Patients must be appropriate candidates for hormone therapy.

          5. Evidence of a personally signed and dated informed consent document indicating that
             the patient or a legally acceptable representative has been informed of all pertinent
             aspects of the study.

        Exclusion Criteria

          1. Any patients who does not agree that Pfizer and companies working with Pfizer use
             his/her information

          2. Known hypersensitivity to letrozole or its excipients or to any CDK4/6 inhibitor
             excipients.

          3. Pregnant women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Tower</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481065&amp;StudyName=Post+Marketing+Surveillance+Study+To+Observe+Safety+And+Efficacy+Of+Ibrance%C2%AE</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481065&amp;StudyName=Post+Marketing+Surveillance+Study+To+Observe+Safety+And+Efficacy+Of+Ibrance%28registered%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer, safety, ibrance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

